Table: monthly_update_prescription_drugs_intro_to_the_market_excel , manufacturer_name like T*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Teva Pharmaceuticals USA	51759052321	Simlandi Pre-Filled Syringe Kit 80mg/0.8mL	2025-01-30	1038.0000	None	1	14600000	None	None	None	None	None	None	Research suggests that there are a total of approximately 14,600,000 patients who suffer from the various conditions that Simlandi is indicated to treat	None
Teva Pharmaceuticals USA	51759038622	Simlandi (2 syringe) Pre-Filled Syringe Kit 20mg/0.2mL	2025-01-30	1038.0000	None	1	14600000	None	None	None	None	None	None	Research suggests that there are a total of approximately 14,600,000 patients who suffer from the various conditions that Simlandi is indicated to treat	None
Teva Pharmaceuticals USA	51759050532	SELARSDI Prefilled Syringe 45 mg/0.5 mL	2025-02-24	2088.2100	None	1	9688000	None	None	None	None	None	None	Research suggests that there are a total of approximately 9,688,000 patients who suffer from the various conditions that Simlandi is indicated to treat	None
Teva Pharmaceuticals USA	51759060732	SELARSDI Prefilled Syringe 90 mg/mL	2025-02-24	4176.4300	None	1	9688000	None	None	None	None	None	None	Research suggests that there are a total of approximately 9,688,000 patients who suffer from the various conditions that Simlandi is indicated to treat	None
Teva Pharmaceuticals USA	00480925708	OCTREOTIDE ACETATE INJ 10MG/VIAL KIT 1	2025-03-20	3044.2500	None	1	9330	None	1	None	None	None	None	Research suggests that as many as 9,330 Americans, in total, suffer from the conditions that this product is indicated to treat. Acquisition fields left blank; Teva developed the product.	None
Teva Pharmaceuticals USA	51759070813	SELARSDI Single Dose Vial 130mg/26mL	2025-04-07	1400.0000	None	1	9688000	None	None	None	None	None	None	Research suggests that there are a total of approximately 9,688,000 patients who suffer from the various conditions that Selarsdi is indicated to treat	None
Tilde Sciences LLC	83649055801	Vecamyl Oral Tablet 2.5 MG, 100 count bottle	2025-03-24	6940.0000	None	1	150	None	None	2023-09-22	650000.0000	None	Drug was acquired with another asset in a bankruptcy. Price provided is inclusive of the other asset. Company was required to relabel drug prior to disribution.	At the point of acquisition, the drug was in shortage. The company worked with the CDMO to identify a new API manufacturer and has been working with the FDA to provide stability data. At this time the company is waiting for FDA approval to relaunch the product. Approval is expected as early as 4/1/2025.	None